Author

K. J. Kowalski

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:drug response / drug discovery· 2 Assay:whole-exome sequencing· 2 Approach:experimental assay· 1 Approach:mechanistic / dynamical model· 1 Approach:statistical model· 1 Research Focus:variant calling· 1

Frequent Co-Authors

N. Wagle· 3 shared P. Mao· 3 shared A. G. Waks· 2 shared E. P. Winer· 2 shared G. N. Johnson· 2 shared N. U. Lin· 2 shared O. Cohen· 2 shared S. A. Wander· 2 shared

Activity by Year

2019-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

N. Wagle

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivAug 25, 2020

Cell line-specific network models of ER+ breast cancer identify PI3Kα inhibitor sensitivity factors and drug combinations

J. Gomez Tejeda Zanudo, P. Mao, C. Alcon…·N. Wagle

DOI 10.1158/0008-5472.can-21-1208

humanmechanistic / dynamical model

𝕏 PostBluesky

Cancer BiologybioRxivNov 28, 2019

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer

S. A. Wander, O. Cohen, X. Gong…·N. Wagle

The paper identifies eight resistance mechanisms to CDK4/6 inhibitors in HR+ breast cancer, present in 80% of resistant tumors, with potential therapeutic strategies.

DOI 10.1158/2159-8290.cd-19-1390

humanwhole-exome sequencing

𝕏 PostBluesky

Cancer BiologybioRxivOct 7, 2019

Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer

P. Mao, O. Cohen, K. J. Kowalski…·N. Wagle

This study identifies FGFR and FGF pathway alterations as acquired resistance mechanisms to ER-targeted therapy in ER+ metastatic breast cancer and suggests targeted inhibitors as potential treatments.

DOI 10.1158/1078-0432.ccr-19-3958

humanwhole-exome sequencing

𝕏 PostBluesky